StreetAlpha.app
Home › Stocks › PYPD

PolyPid Ltd. (PYPD)

$6.54
▲ +6.34%
LAST CLOSE · NOV 17

PolyPid develops drug candidates that release medicine slowly at the treatment site, led by D-PLEX100 for preventing surgical site infections. It last closed at $6.54 on Nov 17, up 6.34% on the day. PYPD reports earnings on Wed, Feb 10, 2027.

AI Auto Pilots
Is PYPD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$34.2M
Free cash flow
−$28.1M
Balance sheet
Cash & equivalents
$6.4M
At Dec 31
Shareholder equity
$11.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$42.6M−$42.6MFY2021FY2022: −$39.6M−$39.6MFY2022FY2023: −$23.9M−$23.9MFY2023FY2024: −$29.0M−$29.0MFY2024FY2025: −$34.2M−$34.2MFY2025

From PYPD's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 25). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
-$0.13
$6.0M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PYPD in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 52.9% upside

Based on 1 analyst who set a price target on PYPD in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $6.54.

Low $10.00Avg $10.00High $10.00
Blue marker: last close $6.54
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
OppenheimerInitiated
Oct 27Buy$10
HC Wainwright & Co.Reiterated
Jul 21Buy$13
DateFirmActionRatingPrice target
Oct 27OppenheimerInitiatedBuy$10
Jul 21HC Wainwright & Co.ReiteratedBuy$13
Loading…

Technical Analysis

PYPD · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 11% above its 20 day and 17% above its 50 day average. It is 26% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 67), near overbought. The nearest support is the Pivot at $6.42, and the nearest resistance the Pivot R1 at $6.66.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.9%/day
Key levels
$7.1152 week high+8.7%
$7.11Swing high (Nov 11)+8.7%
$6.66Pivot R1+1.8%
$6.54Last close
$6.42Pivot−1.8%
$6.31Pivot S1−3.5%
$5.8120 day average−11.2%
$5.4150 day average−17.3%
$5.27Swing low (Nov 2)−19.4%
$5.14100 day average−21.4%
$4.81200 day average−26.5%
$3.5052 week low−46.5%
Indicators
RSI (14)66.69Strong, overbought above 70Neutral
MACD0.33Above its signal lineBullish
Stochastic56.9Middle of its rangeNeutral
ADX (14)24.4Weak trend
Williams %R-31.0Oversold below −80, overbought above −20Neutral
CCI (20)102.0Oversold below −100, overbought above 100Overbought
Rate of change+19.8%Change over 10 sessionsBullish
ATR (14)$0.39Typical daily range, 5.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PYPD

What happened before

See how PYPD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PYPD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PYPD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PYPD in the last 90 days.

Loading…

See today’s whale options flow across the market →

PYPD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼11 buying vs 16 selling
  • ▼Shares held by funds -21.9%
  • ▼Funds holding -8
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding2533−24.2%
In funds' top 1001−100.0%
Held by funds–––
New / increased2 / 914 / 5−42.1%
Reduced / sold out6 / 106 / 0+166.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PYPD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYPD is in one of them and how their past PYPD trades turned out.

PYPD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PYPD in an article yet. Here's the latest on the wider market.

About PolyPid

PolyPid is a biopharmaceutical company based in Petach Tikva, Israel. It develops medicines that release drugs slowly and locally at the site of treatment. Its lead product candidate, D-PLEX100, combines its PLEX technology with the antibiotic doxycycline and is placed directly into the surgical site during surgery to help prevent surgical site infections. The company is also developing treatments for metabolic diseases and cancer, and it plans to license its PLEX technology to other drug developers. Its intended users are surgical patients and the hospitals that treat them.

Headquarters
Petach Tikva, Israel